JPWO2020051374A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020051374A5 JPWO2020051374A5 JP2021512393A JP2021512393A JPWO2020051374A5 JP WO2020051374 A5 JPWO2020051374 A5 JP WO2020051374A5 JP 2021512393 A JP2021512393 A JP 2021512393A JP 2021512393 A JP2021512393 A JP 2021512393A JP WO2020051374 A5 JPWO2020051374 A5 JP WO2020051374A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- modified
- cell
- csr
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims 40
- 108090000765 processed proteins & peptides Proteins 0.000 claims 19
- 229920001184 polypeptide Polymers 0.000 claims 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims 16
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims 8
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims 7
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 150000007523 nucleic acids Chemical group 0.000 claims 4
- 102000006306 Antigen Receptors Human genes 0.000 claims 3
- 108010083359 Antigen Receptors Proteins 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 108091008874 T cell receptors Proteins 0.000 claims 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 3
- 230000001086 cytosolic effect Effects 0.000 claims 3
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 230000004936 stimulating effect Effects 0.000 claims 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 2
- 102000043129 MHC class I family Human genes 0.000 claims 2
- 108091054437 MHC class I family Proteins 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 230000000735 allogeneic effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 230000000861 pro-apoptotic effect Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000019491 signal transduction Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 claims 1
- 101710197873 HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 claims 1
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 claims 1
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 claims 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 230000006399 behavior Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024217381A JP2025028160A (ja) | 2018-09-05 | 2024-12-12 | 同種異系細胞組成物およびその使用方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862727498P | 2018-09-05 | 2018-09-05 | |
| US62/727,498 | 2018-09-05 | ||
| US201862744073P | 2018-10-10 | 2018-10-10 | |
| US62/744,073 | 2018-10-10 | ||
| US201962815334P | 2019-03-07 | 2019-03-07 | |
| US62/815,334 | 2019-03-07 | ||
| US201962815880P | 2019-03-08 | 2019-03-08 | |
| US62/815,880 | 2019-03-08 | ||
| PCT/US2019/049816 WO2020051374A1 (en) | 2018-09-05 | 2019-09-05 | Allogeneic cell compositions and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024217381A Division JP2025028160A (ja) | 2018-09-05 | 2024-12-12 | 同種異系細胞組成物およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021536249A JP2021536249A (ja) | 2021-12-27 |
| JPWO2020051374A5 true JPWO2020051374A5 (enExample) | 2022-09-12 |
| JP7605735B2 JP7605735B2 (ja) | 2024-12-24 |
Family
ID=68136519
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021512393A Active JP7605735B2 (ja) | 2018-09-05 | 2019-09-05 | 同種異系細胞組成物およびその使用方法 |
| JP2024217381A Pending JP2025028160A (ja) | 2018-09-05 | 2024-12-12 | 同種異系細胞組成物およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024217381A Pending JP2025028160A (ja) | 2018-09-05 | 2024-12-12 | 同種異系細胞組成物およびその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220389077A1 (enExample) |
| EP (1) | EP3847197A1 (enExample) |
| JP (2) | JP7605735B2 (enExample) |
| KR (1) | KR20210073520A (enExample) |
| CN (2) | CN119119296A (enExample) |
| AU (1) | AU2019335014A1 (enExample) |
| CA (1) | CA3111384A1 (enExample) |
| WO (1) | WO2020051374A1 (enExample) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111727256A (zh) * | 2017-09-08 | 2020-09-29 | 波赛达治疗公司 | 用于嵌合配体受体（clr）-介导的条件性基因表达的组合物和方法 |
| EP3773626A4 (en) * | 2018-03-28 | 2022-01-05 | Board of Regents, The University of Texas System | USING HISTONE MODIFIERS TO REPROGRAM LYMPHOCYTES AND EFFECTORS |
| SG10201802979VA (en) * | 2018-04-10 | 2019-11-28 | Kah Meng Lim | Immunological extract and method of production |
| JP7558167B2 (ja) | 2018-12-03 | 2024-09-30 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | オリゴベンズアミド類似体およびがん処置におけるそれらの使用 |
| JP7650818B2 (ja) | 2019-04-26 | 2025-03-25 | アロジーン セラピューティクス，インコーポレイテッド | 同種ｃａｒ ｔ細胞を製造する方法 |
| KR20220057596A (ko) * | 2019-09-05 | 2022-05-09 | 포세이다 테라퓨틱스, 인크. | 동종이계 세포 조성물 및 사용 방법 |
| IL294388A (en) * | 2020-01-14 | 2022-08-01 | Synthekine Inc | Il2 orthologs and methods of use |
| US20230121433A1 (en) * | 2020-03-11 | 2023-04-20 | Poseida Therapeutics, Inc. | Chimeric stimulatory receptors and methods of use in t cell activation and differentiation |
| KR20210121585A (ko) * | 2020-03-30 | 2021-10-08 | 한국세라믹기술원 | 반응성 및 안정성 그리고 항체회수가 향상된 z-도메인 및 칼시퀘스트린 융합단백질 및 이를 이용한 항체의 분리 및 정제 방법 |
| EP4189072A4 (en) * | 2020-07-29 | 2024-09-18 | Eureka Therapeutics, Inc. | T-CELLS AND CHIMERIC STIMULATING RECEPTORS AND USES THEREOF |
| CN112375138B (zh) * | 2020-11-13 | 2022-12-13 | 中元汇吉生物技术股份有限公司 | 一种重组载脂蛋白e和应用 |
| CN112480242B (zh) * | 2020-12-04 | 2023-06-06 | 中国人民解放军陆军军医大学 | Spink7蛋白在制备预防和/或治疗溃疡性结肠炎的药物中的应用 |
| CN112402592B (zh) * | 2020-12-04 | 2023-06-02 | 中国人民解放军陆军军医大学 | Spink7蛋白在制备促进过度炎症创面愈合的药物中的应用 |
| CN116887850A (zh) * | 2020-12-18 | 2023-10-13 | 卡利南安伯公司 | 双功能性线融合胶原定位的免疫调节分子及其制备方法 |
| CN112941039A (zh) * | 2021-02-01 | 2021-06-11 | 南京大学 | 一种新型类囊泡溶瘤病毒及其在制备抗肿瘤药物上的应用 |
| WO2022192895A1 (en) * | 2021-03-10 | 2022-09-15 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Compositions and methods to reduce therapeutic t cell toxicity |
| CN113249361A (zh) * | 2021-03-29 | 2021-08-13 | 南京欧凯生物科技有限公司 | 基质金属蛋白酶及其制备方法 |
| IL307598A (en) | 2021-04-16 | 2023-12-01 | Juno Therapeutics Inc | T-cell therapy in patients who have had a previous stem cell transplant |
| US12064466B2 (en) * | 2021-04-27 | 2024-08-20 | Academia Sinica | Methods of treating hypertriglyceridemia or hypertriglyceridemia-related diseases |
| CN113481185B (zh) * | 2021-08-05 | 2022-12-02 | 云南师范大学 | 一种耐盐β-半乳糖苷酶GalNC2-13及其制备方法和应用 |
| CN113846070B (zh) * | 2021-10-18 | 2023-05-16 | 翌圣生物科技(上海)股份有限公司 | 高活性的mTET2酶突变体、其编码DNA及其应用 |
| EP4426339A1 (en) | 2021-11-03 | 2024-09-11 | Celgene Corporation | Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma |
| CN113957075B (zh) * | 2021-11-22 | 2023-04-07 | 百世诺(北京)医学检验实验室有限公司 | 突变的遗传性心律失常基因及其应用 |
| CN116178562A (zh) * | 2021-11-29 | 2023-05-30 | 四川大学华西医院 | 基于efna1构建的嵌合抗原受体免疫细胞制备及其应用 |
| WO2023098729A1 (en) * | 2021-11-30 | 2023-06-08 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric genes |
| CN114539376B (zh) * | 2022-01-17 | 2023-06-13 | 中国水产科学研究院南海水产研究所 | 拟穴青蟹生物标记物cyp2基因及其在制备病理检测试剂中的应用 |
| CN114487448B (zh) * | 2022-01-21 | 2022-10-18 | 天津天海新域生物科技有限公司 | 用于检测重症肌无力相关抗体的组合物、试剂盒及应用 |
| JP2025504002A (ja) | 2022-01-28 | 2025-02-06 | ジュノー セラピューティクス インコーポレイテッド | 細胞組成物を製造する方法 |
| CN114113639B (zh) * | 2022-01-29 | 2022-04-19 | 北京大有天弘科技有限公司 | 一种血型抗体检测方法及其应用 |
| CN114137231B (zh) * | 2022-01-29 | 2022-04-29 | 北京大有天弘科技有限公司 | 一种血型不规则抗体的检测试剂盒及其应用 |
| CN118742571A (zh) * | 2022-02-09 | 2024-10-01 | 恺兴生命科技(上海)有限公司 | 用于细胞免疫学的组合物和方法 |
| CN114646764B (zh) * | 2022-04-08 | 2024-11-29 | 华南农业大学 | 一种arhgap35蛋白在猪x和y精子鉴定或分离中的应用 |
| US20250302954A1 (en) | 2022-05-11 | 2025-10-02 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| WO2023220641A2 (en) | 2022-05-11 | 2023-11-16 | Juno Therapeutics, Inc. | Methods and uses related to t cell therapy and production of same |
| CN114958862B (zh) * | 2022-05-23 | 2023-12-08 | 郑州伊美诺生物技术有限公司 | 检测慢性间质性肾炎的重组抗原的制备方法 |
| WO2023230581A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Methods of manufacturing t cell therapies |
| WO2023230548A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Method for predicting response to a t cell therapy |
| CN114989287B (zh) * | 2022-06-06 | 2024-04-09 | 孙英贤 | 脱乙酰化修饰的baf155蛋白及其制药用途 |
| CN114920816B (zh) * | 2022-06-06 | 2024-04-05 | 孙英贤 | Baf155突变基因及其制药用途 |
| EP4562033A1 (en) * | 2022-07-27 | 2025-06-04 | Biocell Innovations Pte. Ltd. | Production of cells and viral vectors |
| CN115747170B (zh) * | 2022-08-29 | 2023-08-04 | 四川大学 | 一种豇豆褪绿斑驳病毒-多肽复合物及其在骨质疏松治疗中的应用 |
| CN115820580A (zh) * | 2022-08-31 | 2023-03-21 | 武汉爱博泰克生物科技有限公司 | 活性重组hTET2蛋白的表达及纯化方法 |
| CN115558712A (zh) * | 2022-09-22 | 2023-01-03 | 华中科技大学同济医学院附属协和医院 | Fam177a1的新用途 |
| CN115850512B (zh) * | 2022-10-14 | 2025-11-07 | 江苏大学 | 一种用于靶向治疗肿瘤的重组融合蛋白及其制备方法 |
| EP4611798A1 (en) | 2022-11-02 | 2025-09-10 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
| CN115976004B (zh) * | 2022-12-27 | 2024-07-09 | 天津科技大学 | 一种黄体酮17α-羟化酶突变体及其应用 |
| EP4652153A1 (en) | 2023-01-20 | 2025-11-26 | Poseida Therapeutics, Inc. | Lipidoid compounds and related compositions and uses |
| WO2024168192A1 (en) | 2023-02-10 | 2024-08-15 | Celgene Corporation | Assessment of bcma in biological samples |
| GB2626983A (en) * | 2023-02-10 | 2024-08-14 | Quell Therapeutics Ltd | Protein |
| CN116253778B (zh) * | 2023-03-03 | 2025-09-23 | 中山大学 | 一种缓解长春新碱致神经病理性疼痛的多肽及其应用 |
| CN118109416B (zh) * | 2023-03-30 | 2024-11-22 | 广州百吉生物制药有限公司 | 功能增强型工程化免疫细胞及其制备和应用 |
| AU2024244453A1 (en) | 2023-04-05 | 2025-11-13 | Poseida Therapeutics, Inc. | Transposase polynucleotides and uses thereof |
| AU2024243923A1 (en) | 2023-04-05 | 2025-11-13 | Poseida Therapeutics, Inc. | Chimeric transposases and uses thereof |
| WO2024211512A2 (en) | 2023-04-05 | 2024-10-10 | Poseida Therapeutics, Inc. | Transposases and uses thereof |
| CN116478271B (zh) * | 2023-06-19 | 2023-08-29 | 青岛大学 | 半滑舌鳎抗病基因PPARα及其编码蛋白的应用 |
| CN119320771A (zh) * | 2023-07-17 | 2025-01-17 | 北京艺妙神州医药科技有限公司 | 用于敲除t细胞中的trac和b2m的试剂和方法 |
| CN116948015B (zh) * | 2023-07-18 | 2024-07-05 | 山西锦波生物医药股份有限公司 | 生物合成人体结构性材料xxii型胶原蛋白的方法 |
| WO2025029930A1 (en) * | 2023-07-31 | 2025-02-06 | Legend Biotech Ireland Limited | Cells overexpressing cd31 and methods of use thereof |
| CN116854801A (zh) * | 2023-08-21 | 2023-10-10 | 广东省人民医院 | Hand1重组蛋白及其制备方法和在治疗扩张性心肌病药物中的应用 |
| WO2025049925A2 (en) | 2023-09-01 | 2025-03-06 | Poseida Therapeutics, Inc. | Lipidoid compounds and related compositions and uses |
| WO2025055927A1 (en) * | 2023-09-13 | 2025-03-20 | Qihan Hong Kong Limited | Immunotherapies using hypoimmunogenic engineered cells |
| WO2025064507A1 (en) | 2023-09-19 | 2025-03-27 | Poseida Therapeutics, Inc. | Compositions and methods for integration of viral vectors |
| CN117586418B (zh) * | 2023-11-08 | 2025-07-15 | 东南大学 | 一种丝氨酸蛋白酶抑制剂及其应用 |
| WO2025106376A1 (en) * | 2023-11-17 | 2025-05-22 | Dna Twopointo Inc. | Mammalian cell lines for transient protein production |
| CN117551621B (zh) * | 2023-11-20 | 2024-04-30 | 梅州市人民医院(梅州市医学科学院) | 一种杂交瘤细胞株l008、单克隆抗体及其应用 |
| CN117883382B (zh) * | 2023-11-27 | 2025-02-14 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 高效递送疫苗的脂质体载体及脂质体疫苗的制备与用途 |
| CN117820434B (zh) * | 2023-12-31 | 2024-11-19 | 武汉优恩生物科技有限公司 | 牛羊妊娠相关糖蛋白的多肽抗原及应用 |
| WO2025156492A1 (zh) * | 2024-01-23 | 2025-07-31 | 星尘股份有限公司 | 转座酶及其用途 |
| WO2025160432A1 (en) | 2024-01-26 | 2025-07-31 | Poseida Therapeutics, Inc. | Methods and compositions for enhancing in vivo persistence and potency of cell therapy |
| CN117919389B (zh) * | 2024-03-22 | 2024-07-23 | 上海南方模式生物科技股份有限公司 | 肿瘤新抗原dna疫苗 |
| WO2025221789A1 (en) | 2024-04-16 | 2025-10-23 | Poseida Therapeutics, Inc. | Compositions and methods for use in car/tcr cell therapies |
| CN118308420B (zh) * | 2024-04-19 | 2025-06-03 | 东北农业大学 | 一种大豆基因Glyma.18G041900的应用 |
| CN118360271B (zh) * | 2024-05-07 | 2025-12-05 | 中国海洋大学 | 一种脂肪酶突变体及其在提升白酒酯类风味物质中的应用 |
| CN118240829B (zh) * | 2024-05-21 | 2024-07-23 | 华南农业大学 | NompC基因在防治桔小实蝇中的应用 |
| CN119736407A (zh) * | 2024-12-27 | 2025-04-01 | 西北农林科技大学 | 一种提高动物生长速度和大小的stc2基因编码序列突变体的应用 |
| CN119899820A (zh) * | 2025-01-23 | 2025-04-29 | 深圳开悦生命科技有限公司 | Dhx8融合蛋白及其制备方法 |
| CN120209114A (zh) * | 2025-03-07 | 2025-06-27 | 首都医科大学 | 一种含有penk蛋白的组合物及其应用 |
| CN119874865B (zh) * | 2025-03-11 | 2025-11-25 | 东北林业大学 | 一种溪荪ost48蛋白在植物促分蘖中的应用 |
| CN120192430B (zh) * | 2025-03-24 | 2025-08-22 | 安康市中心医院 | 一种基于硒修饰的心肌保护多肽及其制备方法与应用 |
| CN119978086B (zh) * | 2025-03-31 | 2025-10-17 | 中国农业大学 | 一种调控植物生长发育的蛋白质dap1及其编码基因和应用 |
| CN120607598A (zh) * | 2025-05-16 | 2025-09-09 | 安徽大学 | 人源先锋转录因子sox15 hmg结构域重组蛋白及其制备方法 |
| CN120591344A (zh) * | 2025-06-13 | 2025-09-05 | 广州景旸生物科技有限公司 | Col3a1蛋白的制备方法及其应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4766067A (en) | 1985-05-31 | 1988-08-23 | President And Fellows Of Harvard College | Gene amplification |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US4889818A (en) | 1986-08-22 | 1989-12-26 | Cetus Corporation | Purified thermostable enzyme |
| US4795699A (en) | 1987-01-14 | 1989-01-03 | President And Fellows Of Harvard College | T7 DNA polymerase |
| US4921794A (en) | 1987-01-14 | 1990-05-01 | President And Fellows Of Harvard College | T7 DNA polymerase |
| US5130238A (en) | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
| US5142033A (en) | 1988-09-23 | 1992-08-25 | Hoffmann-La Roche Inc. | Structure-independent DNA amplification by the polymerase chain reaction |
| US5091310A (en) | 1988-09-23 | 1992-02-25 | Cetus Corporation | Structure-independent dna amplification by the polymerase chain reaction |
| US5066584A (en) | 1988-09-23 | 1991-11-19 | Cetus Corporation | Methods for generating single stranded dna by the polymerase chain reaction |
| US4994370A (en) | 1989-01-03 | 1991-02-19 | The United States Of America As Represented By The Department Of Health And Human Services | DNA amplification technique |
| US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
| US5580734A (en) | 1990-07-13 | 1996-12-03 | Transkaryotic Therapies, Inc. | Method of producing a physical map contigous DNA sequences |
| US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US5712149A (en) * | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
| EP3783098A1 (en) * | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| JP7054622B2 (ja) * | 2014-07-21 | 2022-04-14 | ノバルティス アーゲー | ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置 |
| GB201415347D0 (en) * | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Signalling system |
| JP6868554B2 (ja) * | 2014-09-02 | 2021-05-12 | ベリカム ファーマシューティカルズ， インコーポレイテッド | ＭｙＤ８８およびＣＤ４０ポリペプチドによるキメラ抗原受容体の共刺激 |
| WO2017222593A1 (en) * | 2016-06-24 | 2017-12-28 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars), compositions and methods thereof |
| IL262366B2 (en) * | 2016-04-15 | 2024-07-01 | Alpine Immune Sciences Inc | Immunomodulatory proteins and CD80 variants and their uses |
| JP2020511136A (ja) * | 2017-03-17 | 2020-04-16 | フレッド ハッチンソン キャンサー リサーチ センター | 免疫調節性融合タンパク質およびその使用 |
| US20190048060A1 (en) * | 2017-08-08 | 2019-02-14 | Sangamo Therapeutics, Inc. | Chimeric antigen receptor mediated cell targeting |
| WO2019173636A1 (en) * | 2018-03-07 | 2019-09-12 | Poseida Therapeutics, Inc. | Cartyrin compositions and methods for use |
-
2019
- 2019-09-05 JP JP2021512393A patent/JP7605735B2/ja active Active
- 2019-09-05 EP EP19782807.2A patent/EP3847197A1/en active Pending
- 2019-09-05 AU AU2019335014A patent/AU2019335014A1/en active Pending
- 2019-09-05 CN CN202411266320.1A patent/CN119119296A/zh active Pending
- 2019-09-05 KR KR1020217010008A patent/KR20210073520A/ko active Pending
- 2019-09-05 US US17/273,030 patent/US20220389077A1/en active Pending
- 2019-09-05 CN CN201980072595.2A patent/CN113383018B/zh active Active
- 2019-09-05 CA CA3111384A patent/CA3111384A1/en active Pending
- 2019-09-05 WO PCT/US2019/049816 patent/WO2020051374A1/en not_active Ceased
-
2024
- 2024-12-12 JP JP2024217381A patent/JP2025028160A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020051374A5 (enExample) | ||
| JP7787119B2 (ja) | Ｐｒａｍｅ陽性がんに対するｔ細胞受容体およびそれを用いた免疫療法 | |
| JP2021036883A5 (enExample) | ||
| Wingren et al. | T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles | |
| AU2020211375B2 (en) | Receptors providing targeted costimulation for adoptive cell therapy | |
| JP2022130485A5 (enExample) | ||
| JP7235316B2 (ja) | 新規ｔ細胞受容体およびそれを用いた免疫療法 | |
| TWI775768B (zh) | 新穎t細胞受器及使用其之免疫治療 | |
| JP7746323B2 (ja) | Ｐｄ－１及び４－１ｂｂの融合タンパク質 | |
| JP2023153142A (ja) | 治療免疫細胞の有効性を改良するための方法 | |
| CN108137670A (zh) | Ny-eso-1特异性tcr及其使用方法 | |
| JP2020511136A5 (enExample) | ||
| Geldres et al. | Chimeric antigen receptor-redirected T cells return to the bench | |
| JP2017512054A (ja) | 三官能性ｔ細胞−抗原カプラ及び方法並びにこれらの使用 | |
| JP2019513394A5 (enExample) | ||
| JP2000516808A (ja) | Ｍｈｃ結合ペプチドオリゴマーおよび使用方法 | |
| JPWO2020033272A5 (enExample) | ||
| JPWO2021071962A5 (enExample) | ||
| US12215134B2 (en) | Engineered immune cells with dominant signals | |
| JPWO2020069184A5 (enExample) | ||
| JP2023544337A (ja) | キメラ抗原受容体発現系 | |
| JPWO2019155288A5 (enExample) | ||
| EP1328290A2 (en) | Expression, preparation, uses, and sequence of recombinantly-derived soluble hla-g | |
| JP7518915B2 (ja) | Ｃｄ３融合タンパク質およびその使用 | |
| CN119301150A (zh) | 人工免疫受体 |